Eton Pharmaceuticals IncNASDAQ:ETON
- LAST PRICE12.4700
- TODAY'S CHANGE (%)0.4400 (3.6575%)
- Bid / Lots12.4000/ 1
- Ask / Lots12.5000/ 1
- Open / Previous Close12.2000 / 12.0300
- Day Range
- 52 Week Range
- Volume129,545
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ETON |
|---|---|---|
| 09:32 ET | 13920 | 12.2 |
| 09:33 ET | 2910 | 12.2119 |
| 09:35 ET | 6167 | 12 |
| 09:37 ET | 4500 | 12.13 |
| 09:39 ET | 860 | 12.11 |
| 09:42 ET | 550 | 12.074 |
| 09:44 ET | 1500 | 12.02 |
| 09:46 ET | 768 | 11.97 |
| 09:48 ET | 1546 | 11.9 |
| 09:50 ET | 1200 | 12.0699 |
| 09:51 ET | 300 | 12.05 |
| 09:53 ET | 3455 | 11.91 |
| 09:55 ET | 1355 | 12.07 |
| 09:57 ET | 640 | 12.18 |
| 10:00 ET | 5555 | 12.25 |
| 10:02 ET | 6110 | 12.32 |
| 10:04 ET | 5697 | 12.3588 |
| 10:06 ET | 4849 | 12.4 |
| 10:08 ET | 5675 | 12.445 |
| 10:09 ET | 10974 | 12.5 |
| 10:11 ET | 3200 | 12.45 |
| 10:13 ET | 7158 | 12.4 |
| 10:15 ET | 5997 | 12.4 |
| 10:18 ET | 3747 | 12.44 |
| 10:20 ET | 7034 | 12.49 |
| 10:22 ET | 6453 | 12.47 |
Today
Yesterday
*DJ Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension), from 6:51AM ET on Monday Nov 25, 2024 by Dow Jones
6:51AM ET on Monday Nov 25, 2024 by Dow JonesEton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension), from 6:50AM ET on Monday Nov 25, 2024 by Dow Jones
6:50AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 13, 2024
DJ Eton Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 8:58AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:58AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eton Pharmaceuticals Inc | 290.1M | -58.4x | --- |
Cipla Ltd | 14.4B | 0.0x | --- |
Zevra Therapeutics Inc | 511.6M | -4.9x | --- |
Scilex Holding Co | 99.9M | -0.4x | --- |
Aoxing Pharmaceutical Company Inc | 4.9M | -0.4x | --- |
Universe Pharmaceuticals Inc | 3.0M | 0.0x | --- |
Company Information
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company's commercial rare disease products include ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ET-400 is a patented formulation of liquid hydrocortisone. It has United States rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus.
Contact Information
- Headquarters
- 21925 W Field Pkwy Ste 235DEER PARK, IL, United States 60010-7278
- Phone
- 847-787-7361
- Fax
- ---
Executives
- Independent Chairman of the Board
- Norbert Riedel
- President, Chief Executive Officer, Director
- Sean Brynjelsen
- Chief Financial Officer, Treasurer, Company Secretary
- James Gruber
- Chief Business Officer
- David Krempa
- Independent Director
- Jennifer Adams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $290.1M |
|---|---|
Revenue (TTM) | $34.7M |
Shares Outstanding | 25.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.33 |
EPS | $-0.21 |
Book Value | $0.60 |
P/E Ratio | -58.4x |
Price/Sales (TTM) | 8.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
